Oxiglutatione
As of the edition of 20 October 2026, Oxiglutatione is a small molecule: marketed, first approved in 1982 (US); acts on GSR; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Bss Plus
- First approved
- 1 January 1982 (US)
- Approvals on record
- 4 in 2 regions
- Holder of the most recent approval
- Alcon; 2 holders in all
- Registered trials
- 1, 0 stopped early
- Disease areas
- Eye; Inherited and neonatal
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Oxiglutatione.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| GSR | Glutathione reductase, mitochondrial | P00390 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 1 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Alcon | Applicant | 1982 to now |